The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Despite remarkable improvements treatment of pediatric acute over last years, relapse still carries a poor prognosis with considerable morbidity and mortality. New immunotherapeutic approaches will change way we treated our patients results had. Blinatumomab bispecific T-cell-engaging antibody indicated for relapsed/refractory B-cell leukemia. The use relapsed ALL has shown promising effects, especially as bridging tool to hematopoietic stem cell transplantation. therapy high risk group remain far from optimal due refractoriness chemotherapy, death infectious complications, well chemotherapy toxicity. This article demonstrates experience using children high-risk according ALL-REZ 2016 protocol. study was approved by Independent Ethics Committee Scientific Council Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. efficacy toxicity innovational blocks fludarabine clofarabine subsequent infusion are shown. And present autologous CD3 + lymphocytes once week during continuous blinatumomab therapy. Also demonstrate refractory first line B-lymphoblastic second ALL. these carried out 2014 Our show an improved reduction minimal residual disease increased event free survival